Introducing the UK Molecular Radiotherapy Consortium

Introducing the UK Molecular Radiotherapy Consortium

The UK Molecular Radiotherapy Consortium is an alliance of clinicians and patient advocates formed to support equitable access to evidence-based theranostic MRT across the UK.
Read More
New masterclass video to support application of the Readiness Assessment Framework

New masterclass video to support application of the Readiness Assessment Framework

HPP has developed a masterclass video which explains how to apply the Readiness Assessment Framework.
Read More
HPP launches framework to assess health system readiness

HPP launches framework to assess health system readiness

HPP is pleased to launch the Readiness Assessment Framework, which can be used to assess health system readiness for a number of different components of care.
Read More
Call to share experiences of integrating radioligand therapy into care

Call to share experiences of integrating radioligand therapy into care

The Health Policy Partnership wants to better understand what actions and initiatives have taken place to improve the delivery of radioligand therapy.
Read More
SPARC-Europe highlights patient experience of radioligand therapy in new video

SPARC-Europe highlights patient experience of radioligand therapy in new video

SPARC-Europe has released a video of patient testimonies to raise awareness of the benefits of radioligand therapy and outline some of the challenges to access.
Read More
New templates to aid application of the Radioligand Therapy Readiness Assessment Framework

New templates to aid application of the Radioligand Therapy Readiness Assessment Framework

The Health Policy Partnership has published a series of templates to support independent applications of the Radioligand Therapy Readiness Assessment Framework.
Read More
ASH 2021 poster focuses on uptake of radioimmunotherapy for lymphoma

ASH 2021 poster focuses on uptake of radioimmunotherapy for lymphoma

The Health Policy Partnership has published a poster at the 63rd annual meeting of the American Society of Hematology (ASH).
Read More
Leading experts join HPP and Avalere to examine readiness for radioligand therapy in the US

Leading experts join HPP and Avalere to examine readiness for radioligand therapy in the US

The Health Policy Partnership (HPP) and Avalere Health recently held a webinar on the use of radioligand therapy and readiness for its future integration in the US.
Read More
HPP launches policy brief at an event coinciding with ESMO 2021

HPP launches policy brief at an event coinciding with ESMO 2021

HPP was thrilled to launch its new policy brief 'Fostering system readiness in cancer care' on 21 September 2021, at an event coinciding with ESMO 2021.
Read More
Achieving system readiness for radioligand therapy in the UK: the event as it happened

Achieving system readiness for radioligand therapy in the UK: the event as it happened

On 9 September, The Health Policy Partnership (HPP) was pleased to host a webinar to launch the UK situation analysis report and policy action blueprint.
Read More
Radioligand Therapy Readiness Assessment Framework launched at event with esteemed speakers

Radioligand Therapy Readiness Assessment Framework launched at event with esteemed speakers

On 9 June 2021, the new Radioligand Therapy Readiness Assessment Framework was launched at an event with a panel of international and multidisciplinary experts.
Read More
New poster on radioligand therapy readiness published at virtual ESMO congress

New poster on radioligand therapy readiness published at virtual ESMO congress

The Health Policy Partnership and Professor Ken Herrmann have published a poster at the virtual European Society for Medical Oncology (ESMO) congress 2020.
Read More